Archibone
Rheumatoid Arthritis And Osteoarthritis Recovery, And Cartilage Restore
Hcbiopharm Llc
Human Otc Drug
NDC 80353-551Archibone also known as Rheumatoid Arthritis And Osteoarthritis Recovery, And Cartilage Restore is a human otc drug labeled by 'Hcbiopharm Llc'. National Drug Code (NDC) number for Archibone is 80353-551. This drug is available in dosage form of Capsule. The names of the active, medicinal ingredients in Archibone drug includes Achyranthes Japonica Root - 1 [hp_X]/1 Prunus Persica Whole - 1 [hp_X]/1 . The currest status of Archibone drug is Active.
Drug Information:
| Drug NDC: | 80353-551 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Archibone |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Rheumatoid Arthritis And Osteoarthritis Recovery, And Cartilage Restore |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Hcbiopharm Llc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Capsule |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | ACHYRANTHES JAPONICA ROOT - 1 [hp_X]/1
PRUNUS PERSICA WHOLE - 1 [hp_X]/1
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | ORAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 19 Nov, 2021 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 14 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | HCBIOPHARM LLC
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | IM19VOE23G
4E7YW35Q0H
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 80353-551-01 | 1 BOTTLE in 1 BOX (80353-551-01) / 1 CAPSULE in 1 BOTTLE (80353-551-02) / 60 CAPSULE in 1 CAPSULE (80353-551-03) | 19 Nov, 2021 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose reverses rheumatoid arthritis and osteoarthritis, rebuilds cartilage, and relieves joint pain*
Product Elements:
Archibone rheumatoid arthritis and osteoarthritis recovery, and cartilage restore rehmannia glutinosa root panax ginseng whole lycium chinense fruit achyranthes japonica root achyranthes japonica root glucosamine hydrochloride prunus persica whole prunus persica whole eucommia ulmoides bark
Indications and Usage:
Use to reverse rheumatoid arthritis to reverse osteoarthritis to rebuild cartilage to relieve joint pain
Warnings:
Warning individuals with known medical conditions should consult a doctor prior to using this.
Dosage and Administration:
Directions take two (2) capsules a day.
Package Label Principal Display Panel:
Package label display archibone rheumatoid arthritis recovery osteoarthritis recovery cartilage restore joint pain relief homeopathic 60 capsules archibone